#glp-1 agonists

Mar 17, 2026 Nutrition

Semaglutide vs. Bariatric Surgery for Heart Health

Does semaglutide protect the heart as well as bariatric surgery? Compare MACE, heart failure, blood pressure, and the limits of current evidence.

semaglutide tirzepatide glp-1 agonists bariatric surgery

Read article →

Mar 14, 2026 Obesity Pharmacology

GLP-1 Receptor Agonists for Obesity: Benefits and Risks

GLP-1 drugs deliver unusually large weight loss and may improve cardiovascular outcomes, but GI effects, lean mass, surgery, and long-term use complicate choice.

semaglutide tirzepatide glp-1 agonists weight loss

Read article →

Mar 10, 2026 Sarcopenia

Do GLP-1 Drugs Cause Muscle Loss? What Human Data Show

Do Ozempic and other GLP-1 drugs cause muscle loss? Review the uncertain human evidence, the concern for older adults with type 2 diabetes, and practical safeguards.

glp-1 agonists ozempic wegovy lean mass loss

Read article →

Mar 6, 2026 Metabolic Health

Metabolic Syndrome: What Beats Drugs, and What Adds to Them

A 2026 meta-analysis ranked diet, exercise, and drugs for metabolic syndrome. The surprise result needs context, and GLP-1 plus exercise changes it.

metabolic syndrome glp-1 agonists metformin lifestyle intervention

Read article →

Mar 1, 2026 Drug Safety

GLP-1 Drugs and Sudden Vision Loss: What the NAION Data Show

A large meta-analysis links GLP-1 drugs to NAION, a rare cause of sudden vision loss. The signal is small, observational, and not confirmed in trials.

glp-1 agonists ozempic semaglutide optic neuropathy

Read article →

Feb 28, 2026 Cardiovascular Health

GLP-1 Drugs in Obese Heart Failure: Where the Benefit Is

A 2025 meta-analysis suggests GLP-1 drugs help some obese heart failure patients, but the signal looks strongest in HFpEF, not HFrEF.

semaglutide glp-1 agonists heart failure hfpef

Read article →

Feb 28, 2026 Weight Loss

Semaglutide Rebound: What the STEP 4 Trial Actually Shows

58% of semaglutide weight loss returns within a year of stopping. STEP 4 data, discontinuation rates, and why this is a policy crisis with cardiac stakes.

semaglutide glp-1 agonists weight rebound metabolic rebound

Read article →

Feb 28, 2026 Cardiovascular Health

GLP-1 Drugs in Heart Failure: Real Promise, Tight Limits

Meta-analyses suggest GLP-1 drugs help obese patients with HFpEF feel and function better, but no trial has shown longer survival or clear benefit in HFrEF.

glp-1 agonists heart failure semaglutide hfpef

Read article →

← PreviousPage 2 of 2